Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
Find out more about us
25 March 2021
16 February 2021
01 February 2021
Find out more
The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19
Sareum has an innovative pipeline of drug development candidates.
LSX World Congress, Feb 2021 (Video)IMC Full Year Results, Oct 2020 (Slides)Proactive Investors, Aug 2020 (Video)BIO Digital, June 2020 (Slides)
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Full-year Results 2020 ¦ Brochure Jan 2021
Annual Report 2020 ¦